![Effectiveness of less than three doses of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia when administered using a standard dose spacing schedule: Observational cohort of young women in Australia - ScienceDirect Effectiveness of less than three doses of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia when administered using a standard dose spacing schedule: Observational cohort of young women in Australia - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2405852115000063-gr1.jpg)
Effectiveness of less than three doses of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia when administered using a standard dose spacing schedule: Observational cohort of young women in Australia - ScienceDirect
![Single-dose HPV vaccination efficacy among adolescent girls and young women in Kenya (the KEN SHE Study): study protocol for a randomized controlled trial | Trials | Full Text Single-dose HPV vaccination efficacy among adolescent girls and young women in Kenya (the KEN SHE Study): study protocol for a randomized controlled trial | Trials | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs13063-021-05608-8/MediaObjects/13063_2021_5608_Fig1_HTML.png)
Single-dose HPV vaccination efficacy among adolescent girls and young women in Kenya (the KEN SHE Study): study protocol for a randomized controlled trial | Trials | Full Text
![Updated Recommendations on Human Papillomavirus Vaccines: 9-valent HPV vaccine and clarification of minimum intervals between doses in the HPV immunization schedule - Canada.ca Updated Recommendations on Human Papillomavirus Vaccines: 9-valent HPV vaccine and clarification of minimum intervals between doses in the HPV immunization schedule - Canada.ca](https://www.canada.ca/content/dam/hc-sc/healthy-canadians/migration/publications/healthy-living-vie-saine/human-papillomavirus-9-valent-vaccine-update-recommendation-mises-a-jour-recommandations-papillome-humain-vaccin-nonavalent/alt/fig01-eng.jpg)
Updated Recommendations on Human Papillomavirus Vaccines: 9-valent HPV vaccine and clarification of minimum intervals between doses in the HPV immunization schedule - Canada.ca
![Uptake of HPV vaccination among boys after the introduction of gender-neutral HPV vaccination in Germany before and during the COVID-19 pandemic | Infection Uptake of HPV vaccination among boys after the introduction of gender-neutral HPV vaccination in Germany before and during the COVID-19 pandemic | Infection](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs15010-023-01978-0/MediaObjects/15010_2023_1978_Fig1_HTML.png)
Uptake of HPV vaccination among boys after the introduction of gender-neutral HPV vaccination in Germany before and during the COVID-19 pandemic | Infection
![The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study - The Lancet The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study - The Lancet](https://www.thelancet.com/cms/asset/e098b13a-fb9a-40e1-a1d2-efa31048c379/gr1.jpg)
The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study - The Lancet
![Milestones and timelines in the late stage clinical development and... | Download Scientific Diagram Milestones and timelines in the late stage clinical development and... | Download Scientific Diagram](https://www.researchgate.net/publication/318383107/figure/fig1/AS:713973976551426@1547236069855/Milestones-and-timelines-in-the-late-stage-clinical-development-and-licensure-of-HPV.png)
Milestones and timelines in the late stage clinical development and... | Download Scientific Diagram
![Updated Recommendations on Human Papillomavirus Vaccines: 9-valent HPV vaccine and clarification of minimum intervals between doses in the HPV immunization schedule - Canada.ca Updated Recommendations on Human Papillomavirus Vaccines: 9-valent HPV vaccine and clarification of minimum intervals between doses in the HPV immunization schedule - Canada.ca](https://www.canada.ca/content/dam/hc-sc/healthy-canadians/migration/publications/healthy-living-vie-saine/human-papillomavirus-9-valent-vaccine-update-recommendation-mises-a-jour-recommandations-papillome-humain-vaccin-nonavalent/alt/pdf-eng.jpg)
Updated Recommendations on Human Papillomavirus Vaccines: 9-valent HPV vaccine and clarification of minimum intervals between doses in the HPV immunization schedule - Canada.ca
![Effects of the age of vaccination on the humoral responses to a human papillomavirus vaccine | npj Vaccines Effects of the age of vaccination on the humoral responses to a human papillomavirus vaccine | npj Vaccines](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41541-022-00458-0/MediaObjects/41541_2022_458_Fig1_HTML.png)
Effects of the age of vaccination on the humoral responses to a human papillomavirus vaccine | npj Vaccines
![Vax 2 Stop Cancer on X: "The HPV vaccine is recommended for everyone ages 9–26. The ideal time for vaccination is between ages 9–12, with completion by the 13th birthday. Those ages Vax 2 Stop Cancer on X: "The HPV vaccine is recommended for everyone ages 9–26. The ideal time for vaccination is between ages 9–12, with completion by the 13th birthday. Those ages](https://pbs.twimg.com/media/FNVqX4rWUAovPTA.png)
Vax 2 Stop Cancer on X: "The HPV vaccine is recommended for everyone ages 9–26. The ideal time for vaccination is between ages 9–12, with completion by the 13th birthday. Those ages
![Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial - The Lancet Infectious Diseases Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial - The Lancet Infectious Diseases](https://www.thelancet.com/cms/attachment/b7398432-b3d8-451f-bf8c-7c93973e4933/gr1_lrg.jpg)